

TDMS No. 20011 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

1-Bromopropane

CAS Number: 106-94-5

Date Report Requested: 10/01/2008

Time Report Requested: 09:42:38

First Dose M/F: 07/21/03 / 07/21/03

Lab: BNW

F1_M3

C Number: C20011
Lock Date: 06/15/2006
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.0.0

B6C3F1 MICE MALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	6	13	9	9
Natural Death	7	4	9	5
Survivors				
Terminal Sacrifice	37	33	32	36
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Gallbladder	(40)	(40)	(34)	(38)
Degeneration, Hyaline	2 (5%)			1 (3%)
Hemorrhage				1 (3%)
Hyperplasia	1 (3%)			
Infiltration Cellular, Polymorphonuclear			1 (3%)	
Intestine Large, Rectum	(45)	(48)	(43)	(48)
Inflammation, Suppurative				1 (2%)
Ulcer				1 (2%)
Artery, Inflammation, Chronic Active	1 (2%)			
Intestine Small, Duodenum	(44)	(48)	(43)	(46)
Inflammation, Acute		1 (2%)		
Intestine Small, Jejunum	(44)	(48)	(43)	(46)
Liver	(50)	(50)	(50)	(50)
Angiectasis		3 (6%)		
Basophilic Focus	1 (2%)	2 (4%)	1 (2%)	3 (6%)
Clear Cell Focus	9 (18%)	14 (28%)	16 (32%)	12 (24%)
Eosinophilic Focus	20 (40%)	16 (32%)	8 (16%)	9 (18%)
Fatty Change, Focal	1 (2%)	3 (6%)		5 (10%)
Inflammation, Chronic			1 (2%)	1 (2%)
Mineralization				1 (2%)
Mixed Cell Focus	2 (4%)	7 (14%)	1 (2%)	1 (2%)
Necrosis	5 (10%)	4 (8%)	3 (6%)	9 (18%)
Tension Lipidosis	4 (8%)	3 (6%)	6 (12%)	2 (4%)
Vacuolization Cytoplasmic				1 (2%)
Bile Duct, Hyperplasia				1 (2%)
Mesentery	(9)	(11)	(6)	(7)
Artery, Inflammation				1 (14%)
Artery, Mineralization	1 (11%)			
Fat, Necrosis	7 (78%)	11 (100%)	5 (83%)	5 (71%)
Pancreas	(48)	(50)	(48)	(50)
Atrophy	1 (2%)			1 (2%)

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Basophilic Focus	1 (2%)		1 (2%)	
Cyst	1 (2%)			
Inflammation, Chronic Active	1 (2%)			
Salivary Glands	(49)	(50)	(49)	(50)
Atrophy	1 (2%)		1 (2%)	
Stomach, Forestomach	(47)	(50)	(48)	(50)
Hyperplasia, Squamous	5 (11%)	7 (14%)	5 (10%)	3 (6%)
Inflammation	2 (4%)	2 (4%)	1 (2%)	
Ulcer	2 (4%)	4 (8%)	3 (6%)	2 (4%)
Artery, Inflammation, Chronic Active	1 (2%)			
Stomach, Glandular	(47)	(49)	(47)	(49)
Mineralization	2 (4%)			
Artery, Inflammation, Chronic Active	1 (2%)			
Tooth	(8)	(8)	(9)	(11)
Dysplasia	7 (88%)	8 (100%)	9 (100%)	11 (100%)
Malformation	1 (13%)			

CARDIOVASCULAR SYSTEM

Blood Vessel	(3)	(1)	(0)	(0)
Inflammation, Chronic Active	1 (33%)			
Thrombosis		1 (100%)		
Aorta, Mineralization	2 (67%)			
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	12 (24%)	10 (20%)	14 (28%)	9 (18%)
Hemorrhage				1 (2%)
Inflammation, Acute	1 (2%)			
Mineralization	2 (4%)			
Thrombosis	1 (2%)	2 (4%)	1 (2%)	
Artery, Inflammation, Chronic Active	1 (2%)	1 (2%)		
Epicardium, Inflammation, Chronic		1 (2%)		

ENDOCRINE SYSTEM

Adrenal Cortex	(49)	(50)	(49)	(50)
Hyperplasia	16 (33%)	18 (36%)	14 (29%)	12 (24%)
Hypertrophy	23 (47%)	19 (38%)	22 (45%)	28 (56%)
Subcapsular, Hyperplasia		1 (2%)		
Adrenal Medulla	(50)	(49)	(49)	(50)
Hyperplasia	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Islets, Pancreatic	(48)	(50)	(48)	(50)
Hyperplasia	1 (2%)			
Pituitary Gland	(46)	(48)	(46)	(48)
Cyst			1 (2%)	1 (2%)

B6C3F1 MICE MALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Pars Distalis, Hyperplasia	2 (4%)	2 (4%)	1 (2%)	1 (2%)
Pars Intermedia, Hyperplasia			1 (2%)	
Thyroid Gland	(49)	(50)	(48)	(50)
Follicular Cell, Hyperplasia	1 (2%)			
GENERAL BODY SYSTEM				
Peritoneum	(0)	(0)	(1)	(0)
GENITAL SYSTEM				
Coagulating Gland	(1)	(0)	(0)	(0)
Inflammation, Suppurative	1 (100%)			
Epididymis	(50)	(50)	(50)	(50)
Granuloma Sperm	1 (2%)	1 (2%)	1 (2%)	
Necrosis				2 (4%)
Preputial Gland	(49)	(49)	(50)	(50)
Inflammation, Suppurative			1 (2%)	
Inflammation, Granulomatous			1 (2%)	1 (2%)
Prostate	(49)	(50)	(48)	(50)
Inflammation, Suppurative	2 (4%)		2 (4%)	2 (4%)
Inflammation, Chronic Active			1 (2%)	1 (2%)
Artery, Inflammation, Chronic Active	1 (2%)			
Seminal Vesicle	(48)	(50)	(49)	(50)
Amyloid Deposition	1 (2%)			
Inflammation, Suppurative	1 (2%)			
Inflammation, Chronic Active			1 (2%)	
Testes	(50)	(50)	(50)	(50)
Atrophy	1 (2%)	1 (2%)	1 (2%)	3 (6%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(48)	(48)	(48)	(50)
Lymph Node	(1)	(1)	(3)	(0)
Lymph Node, Bronchial	(23)	(30)	(32)	(31)
Infiltration Cellular, Mixed Cell		1 (3%)		
Lymph Node, Mandibular	(27)	(28)	(21)	(26)
Lymph Node, Mediastinal	(35)	(32)	(35)	(34)
Infiltration Cellular, Mixed Cell		1 (3%)		
Lymph Node, Mesenteric	(48)	(46)	(44)	(48)
Angiectasis	1 (2%)			
Spleen	(48)	(50)	(49)	(50)
Angiectasis		1 (2%)		

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Atrophy	7 (15%)	8 (16%)	2 (4%)	3 (6%)
Congestion	4 (8%)	4 (8%)	1 (2%)	3 (6%)
Hematopoietic Cell Proliferation	20 (42%)	19 (38%)	14 (29%)	16 (32%)
Hyperplasia, Lymphoid	5 (10%)	2 (4%)	5 (10%)	2 (4%)
Infarct	1 (2%)			
Necrosis	1 (2%)			
Necrosis, Lymphoid	1 (2%)		1 (2%)	2 (4%)
Thymus	(38)	(35)	(37)	(32)
Atrophy	13 (34%)	12 (34%)	19 (51%)	12 (38%)
Cyst	5 (13%)	1 (3%)	7 (19%)	4 (13%)
Necrosis, Lymphoid	1 (3%)		1 (3%)	3 (9%)
Medulla, Hyperplasia, Lymphoid	16 (42%)	9 (26%)	14 (38%)	6 (19%)
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion				1 (2%)
Inflammation, Chronic Active	5 (10%)	5 (10%)	3 (6%)	8 (16%)
Ulcer	1 (2%)			
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(49)	(50)	(50)
Hyperostosis		2 (4%)		1 (2%)
Necrosis				1 (2%)
Skeletal Muscle	(0)	(2)	(1)	(2)
NERVOUS SYSTEM				
Brain	(50)	(50)	(49)	(50)
RESPIRATORY SYSTEM				
Larynx	(48)	(50)	(48)	(50)
Vacuolization Cytoplasmic		5 (10%)	10 (21%)	11 (22%)
Lung	(50)	(50)	(49)	(49)
Congestion, Chronic	1 (2%)		1 (2%)	
Hemorrhage	2 (4%)	2 (4%)		1 (2%)
Inflammation, Chronic Active			2 (4%)	
Mineralization	1 (2%)			
Pigmentation		1 (2%)		
Thrombosis	1 (2%)			

B6C3F1 MICE MALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Alveolar Epithelium, Hyperplasia	2 (4%)	2 (4%)	1 (2%)	5 (10%)
Alveolus, Infiltration Cellular, Histiocyte		3 (6%)	1 (2%)	1 (2%)
Bronchiole, Hyperplasia		3 (6%)		1 (2%)
Bronchiole, Necrosis				1 (2%)
Bronchiole, Regeneration	1 (2%)	44 (88%)	38 (78%)	47 (96%)
Bronchiole, Vacuolization Cytoplasmic		18 (36%)	19 (39%)	17 (35%)
Nose	(50)	(50)	(50)	(50)
Foreign Body		1 (2%)		
Inflammation, Suppurative	2 (4%)	3 (6%)	2 (4%)	3 (6%)
Polyp, Inflammatory				3 (6%)
Glands, Hyperplasia		1 (2%)		
Olfactory Epithelium, Atrophy	2 (4%)	4 (8%)	7 (14%)	4 (8%)
Olfactory Epithelium, Metaplasia, Respiratory		7 (14%)	6 (12%)	3 (6%)
Respiratory Epithelium, Hyperplasia	16 (32%)	29 (58%)	23 (46%)	26 (52%)
Respiratory Epithelium, Vacuolization Cytoplasmic		12 (24%)	19 (38%)	20 (40%)
Pleura	(0)	(0)	(1)	(1)
Trachea	(49)	(50)	(47)	(50)
Vacuolization Cytoplasmic		15 (30%)	24 (51%)	24 (48%)
SPECIAL SENSES SYSTEM				
Eye	(45)	(47)	(44)	(47)
Cataract	1 (2%)	1 (2%)	1 (2%)	
Degeneration	1 (2%)	1 (2%)		1 (2%)
Cornea, Inflammation, Acute			1 (2%)	
Cornea, Inflammation, Chronic Active	2 (4%)		1 (2%)	
Retina, Atrophy	1 (2%)		1 (2%)	
Harderian Gland	(46)	(49)	(49)	(48)
Hyperplasia	3 (7%)	4 (8%)	1 (2%)	4 (8%)
URINARY SYSTEM				
Kidney	(49)	(50)	(50)	(49)
Amyloid Deposition				1 (2%)
Cyst		1 (2%)		
Hydronephrosis	1 (2%)			1 (2%)
Infarct	1 (2%)	2 (4%)	3 (6%)	1 (2%)
Inflammation, Suppurative	1 (2%)		2 (4%)	2 (4%)
Metaplasia, Osseous	2 (4%)	1 (2%)		
Mineralization	2 (4%)			
Nephropathy	44 (90%)	46 (92%)	47 (94%)	41 (84%)
Papilla, Necrosis			1 (2%)	
Renal Tubule, Hyperplasia	2 (4%)	1 (2%)	2 (4%)	

TDMS No. 20011 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

1-Bromopropane

CAS Number: 106-94-5

Date Report Requested: 10/01/2008

Time Report Requested: 09:42:38

First Dose M/F: 07/21/03 / 07/21/03

Lab: BNW

B6C3F1 MICE MALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Renal Tubule, Necrosis				1 (2%)
Urethra	(0)	(0)	(0)	(1)
Bulbourethral Gland, Angiectasis				1 (100%)
Urinary Bladder	(47)	(50)	(47)	(48)
Inflammation, Chronic Active	1 (2%)		1 (2%)	1 (2%)
Mineralization	1 (2%)			

*** END OF MALE ***

B6C3F1 MICE FEMALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	10	7	8	8
Natural Death	4	3	5	
Survivors				
Moribund Sacrifice	1			1
Terminal Sacrifice	35	40	37	41
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(43)	(36)	(36)	(44)
Inflammation, Chronic Active		1 (3%)		
Intestine Large, Cecum	(48)	(49)	(46)	(50)
Hemorrhage	1 (2%)			
Inflammation, Suppurative		1 (2%)		
Intestine Large, Colon	(48)	(49)	(46)	(50)
Necrosis	1 (2%)			
Intestine Large, Rectum	(47)	(49)	(46)	(50)
Artery, Inflammation, Chronic Active				1 (2%)
Intestine Small, Duodenum	(46)	(49)	(46)	(50)
Intestine Small, Ileum	(48)	(49)	(46)	(50)
Epithelium, Hyperplasia			1 (2%)	
Intestine Small, Jejunum	(46)	(49)	(46)	(50)
Epithelium, Hyperplasia			1 (2%)	
Liver	(50)	(50)	(50)	(50)
Angiectasis		1 (2%)	1 (2%)	2 (4%)
Basophilic Focus	2 (4%)	3 (6%)	2 (4%)	3 (6%)
Clear Cell Focus	2 (4%)		1 (2%)	2 (4%)
Eosinophilic Focus	6 (12%)	7 (14%)	7 (14%)	5 (10%)
Fatty Change	1 (2%)	1 (2%)		2 (4%)
Fatty Change, Focal	2 (4%)			
Hematopoietic Cell Proliferation			1 (2%)	
Infarct		1 (2%)		
Inflammation, Acute	1 (2%)			
Inflammation, Chronic		1 (2%)	1 (2%)	
Malformation, Lobular			1 (2%)	
Mineralization			1 (2%)	
Mixed Cell Focus	2 (4%)	3 (6%)	3 (6%)	
Necrosis	1 (2%)	1 (2%)	2 (4%)	1 (2%)

B6C3F1 MICE FEMALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Tension Lipidosis	3 (6%)	10 (20%)	4 (8%)	1 (2%)
Thrombosis			1 (2%)	
Vacuolization Cytoplasmic		1 (2%)		
Bile Duct, Hyperplasia		1 (2%)		
Hepatocyte, Mitotic Alteration	1 (2%)			
Mesentery	(11)	(9)	(11)	(13)
Artery, Inflammation	1 (9%)			
Fat, Hemorrhage		1 (11%)	1 (9%)	
Fat, Necrosis	9 (82%)	9 (100%)	9 (82%)	12 (92%)
Pancreas	(50)	(49)	(50)	(50)
Atrophy	7 (14%)	4 (8%)	5 (10%)	2 (4%)
Basophilic Focus	1 (2%)	2 (4%)		
Inflammation, Chronic Active		1 (2%)		1 (2%)
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(49)	(50)
Hyperplasia, Squamous	3 (6%)	2 (4%)	2 (4%)	1 (2%)
Inflammation	1 (2%)			
Ulcer	2 (4%)	2 (4%)		2 (4%)
Artery, Inflammation, Chronic Active				1 (2%)
Stomach, Glandular	(50)	(49)	(48)	(50)
Infiltration Cellular, Mixed Cell		1 (2%)		
Infiltration Cellular, Mononuclear Cell	1 (2%)			
Mineralization			1 (2%)	1 (2%)
Necrosis		1 (2%)	1 (2%)	
Artery, Inflammation, Chronic Active				1 (2%)
Tongue	(0)	(0)	(1)	(0)
Tooth	(0)	(1)	(0)	(0)
Dysplasia		1 (100%)		
CARDIOVASCULAR SYSTEM				
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	6 (12%)	12 (24%)	8 (16%)	8 (16%)
Inflammation, Suppurative			1 (2%)	
Mineralization	3 (6%)		2 (4%)	
Necrosis		1 (2%)		
Thrombosis			2 (4%)	
Artery, Inflammation, Chronic Active	1 (2%)	1 (2%)		
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Hyperplasia	3 (6%)	10 (20%)	4 (8%)	6 (12%)
Hypertrophy	4 (8%)	3 (6%)	1 (2%)	9 (18%)

B6C3F1 MICE FEMALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Inflammation, Suppurative Subcapsular, Hyperplasia		1 (2%)	1 (2%)	1 (2%)
Adrenal Medulla	(50)	(50)	(49)	(50)
Hyperplasia		5 (10%)	1 (2%)	4 (8%)
Islets, Pancreatic	(50)	(49)	(49)	(49)
Hyperplasia		2 (4%)	1 (2%)	
Pituitary Gland	(46)	(49)	(47)	(48)
Pars Distalis, Angiectasis	1 (2%)	1 (2%)	2 (4%)	
Pars Distalis, Hyperplasia	15 (33%)	14 (29%)	11 (23%)	15 (31%)
Pars Intermedia, Hyperplasia		1 (2%)	2 (4%)	
Pars Intermedia, Hypertrophy	1 (2%)	1 (2%)		
Thyroid Gland	(49)	(50)	(46)	(50)
Follicular Cell, Hyperplasia	1 (2%)	1 (2%)	1 (2%)	1 (2%)
GENERAL BODY SYSTEM				
Peritoneum	(0)	(0)	(0)	(1)
GENITAL SYSTEM				
Ovary	(50)	(50)	(50)	(49)
Angiectasis	1 (2%)	2 (4%)		2 (4%)
Congestion, Chronic		1 (2%)		
Cyst	12 (24%)	8 (16%)	12 (24%)	2 (4%)
Hyperplasia, Tubular				1 (2%)
Thrombosis	2 (4%)	2 (4%)		1 (2%)
Uterus	(50)	(50)	(50)	(50)
Angiectasis	2 (4%)	3 (6%)	6 (12%)	3 (6%)
Fibrosis			1 (2%)	
Inflammation, Suppurative			1 (2%)	
Inflammation, Acute	1 (2%)			
Thrombosis	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Endometrium, Hyperplasia, Cystic	39 (78%)	43 (86%)	43 (86%)	41 (82%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(49)	(50)
Angiectasis	2 (4%)			
Atrophy				1 (2%)
Lymph Node	(6)	(5)	(3)	(8)
Iliac, Angiectasis	2 (33%)	1 (20%)		
Iliac, Hyperplasia, Lymphoid	1 (17%)			
Lumbar, Angiectasis		1 (20%)	1 (33%)	1 (13%)

B6C3F1 MICE FEMALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Renal, Angiectasis				1 (13%)
Renal, Hyperplasia, Lymphoid	1 (17%)	1 (20%)		
Lymph Node, Bronchial	(37)	(32)	(39)	(34)
Lymph Node, Mandibular	(45)	(30)	(30)	(37)
Hyperplasia, Lymphoid		1 (3%)		
Lymph Node, Mediastinal	(45)	(39)	(41)	(37)
Hyperplasia, Lymphoid	1 (2%)			
Lymph Node, Mesenteric	(48)	(47)	(47)	(49)
Angiectasis	2 (4%)	2 (4%)		1 (2%)
Hyperplasia, Lymphoid			1 (2%)	
Spleen	(50)	(49)	(50)	(50)
Atrophy	4 (8%)	1 (2%)	2 (4%)	5 (10%)
Congestion			1 (2%)	2 (4%)
Hematopoietic Cell Proliferation	13 (26%)	10 (20%)	13 (26%)	16 (32%)
Hemorrhage				1 (2%)
Hyperplasia, Histiocytic	2 (4%)			
Hyperplasia, Lymphoid	7 (14%)	7 (14%)	5 (10%)	3 (6%)
Hyperplasia, Plasma Cell				1 (2%)
Necrosis, Lymphoid		1 (2%)	1 (2%)	
Pigmentation, Hemosiderin	1 (2%)	2 (4%)		
Thymus	(49)	(45)	(45)	(45)
Atrophy	14 (29%)	13 (29%)	17 (38%)	16 (36%)
Cyst	5 (10%)	7 (16%)	6 (13%)	9 (20%)
Necrosis, Lymphoid		2 (4%)	4 (9%)	
Medulla, Hyperplasia, Lymphoid	25 (51%)	29 (64%)	30 (67%)	26 (58%)
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Hyperplasia	1 (2%)	1 (2%)	1 (2%)	
Skin	(50)	(50)	(50)	(50)
Cyst	1 (2%)			
Inflammation, Chronic Active		4 (8%)	2 (4%)	1 (2%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Cyst		1 (2%)		
Skeletal Muscle	(0)	(0)	(0)	(1)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)

B6C3F1 MICE FEMALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Necrosis		1 (2%)	1 (2%)	
Artery, Inflammation	1 (2%)			
Peripheral Nerve	(1)	(1)	(1)	(1)
Degeneration		1 (100%)		
Spinal Cord	(1)	(1)	(1)	(1)
Inflammation, Chronic Active		1 (100%)		
RESPIRATORY SYSTEM				
Larynx	(50)	(50)	(50)	(50)
Vacuolization Cytoplasmic		3 (6%)	2 (4%)	2 (4%)
Artery, Inflammation, Chronic Active				1 (2%)
Lung	(50)	(50)	(50)	(50)
Inflammation, Chronic Active		1 (2%)		
Alveolar Epithelium, Hyperplasia	1 (2%)	1 (2%)		3 (6%)
Alveolus, Infiltration Cellular, Histiocyte			4 (8%)	1 (2%)
Bronchiole, Hyperplasia	1 (2%)			1 (2%)
Bronchiole, Necrosis			1 (2%)	
Bronchiole, Regeneration		45 (90%)	43 (86%)	49 (98%)
Bronchiole, Vacuolization Cytoplasmic		3 (6%)	4 (8%)	3 (6%)
Nose	(50)	(50)	(50)	(50)
Inflammation, Suppurative				1 (2%)
Olfactory Epithelium, Atrophy				6 (12%)
Olfactory Epithelium, Metaplasia, Respiratory		4 (8%)	5 (10%)	14 (28%)
Respiratory Epithelium, Hyperplasia	11 (22%)	25 (50%)	28 (56%)	27 (54%)
Respiratory Epithelium, Vacuolization		3 (6%)	5 (10%)	8 (16%)
Cytoplasmic				
Pleura	(0)	(0)	(1)	(0)
Trachea	(50)	(49)	(50)	(50)
Vacuolization Cytoplasmic		8 (16%)	7 (14%)	4 (8%)
SPECIAL SENSES SYSTEM				
Eye	(47)	(49)	(45)	(50)
Cataract	3 (6%)	1 (2%)		2 (4%)
Cornea, Hyperplasia, Squamous	1 (2%)			
Cornea, Inflammation, Chronic Active	1 (2%)		2 (4%)	1 (2%)
Cornea, Mineralization	1 (2%)		2 (4%)	1 (2%)
Harderian Gland	(49)	(49)	(48)	(50)
Hyperplasia	3 (6%)	1 (2%)	2 (4%)	6 (12%)
Inflammation, Chronic Active				1 (2%)
Zymbal's Gland	(0)	(1)	(0)	(0)

B6C3F1 MICE FEMALE	CONTROL	62.5 PPM	125 PPM	250 PPM
URINARY SYSTEM				
Kidney	(50)	(49)	(49)	(50)
Amyloid Deposition				1 (2%)
Cyst			1 (2%)	
Inflammation, Suppurative			1 (2%)	
Inflammation, Chronic Active		1 (2%)		
Metaplasia, Osseous	3 (6%)	4 (8%)		2 (4%)
Nephropathy	33 (66%)	37 (76%)	40 (82%)	39 (78%)
Renal Tubule, Hyperplasia			1 (2%)	
Transitional Epithelium, Hyperplasia		1 (2%)		
Urinary Bladder	(50)	(49)	(48)	(50)
Inflammation, Chronic Active			1 (2%)	
Artery, Inflammation, Chronic Active				2 (4%)

*** END OF REPORT ***